Mount Sinai Comprehensive Cancer Center — Miami Beach, Florida

Public research footprint of Mount Sinai Comprehensive Cancer Center, compiled from the ClinicalTrials.gov public registry.

177

Registered studies

Active

Recruiting now

Completed

Stopped or withdrawn

Most-studied conditions

Stage II Bladder Urothelial Carcinoma AJCC v6 and v7 · Lung Non-Small Cell Carcinoma · Metastatic Bladder Clear Cell (Glycogen-Rich) Urothelial Carcinoma · Lung Non-Squamous Non-Small Cell Carcinoma

Recently updated registry entries

NCT02196181 — Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer… (Active Not Recruiting)
NCT03775265 — Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle… (Active Not Recruiting)
NCT02224781 — Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and… (Active Not Recruiting)

7 more recent registry entries at this facility

Enter your work email to view the full list.

I’d also like to receive occasional marketing emails from Eichor for research sites (optional — unsubscribe anytime).

Work at Mount Sinai Comprehensive Cancer Center?

Verify and correct how your facility appears in public registry records — free.

Verify this profile →

Compiled from public registry records (ClinicalTrials.gov) as of August 02, 2026. Counts reflect how this facility appears in registry listings; name variants may exist and are not combined. This page describes public records only and makes no assessment of any facility.